Prostate cancer is the most commonly diagnosed cancer in men and is the second most common cause of male death from cancer. In 2013, approximately 238,590 men in the U.S. will be diagnosed with prostate cancer and an estimated 29,720 will die from it. In addition, there are major population disparities in prostate cancer incidence and mortality, with African American men experiencing 2.5 times greater risk of prostate cancer death compared to Caucasian men. The Prostate Cancer Research Program prioritizes research that will 1) develop better tools to detect clinically relevant disease in asymptomatic men, 2) distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer, and 3) develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer. The focus areas for funded research include biomarker development, genetics, imaging, mechanisms of resistance, survivorship and palliative care, therapy, and tumor and microenvironment biology.
PCRP-Supported Key Research Resources
PCRP Perspectives: Keep Informed on Breakthroughs in Prostate Cancer Research
Innovative Minds in Prostate Cancer Today
The IMPaCT 2011 Conference was held March 9-12, 2011 in Orlando, Florida. Click here for more information.
Congressional Appropriations
- $1.21 billion FY97-12
- $80 million FY13
Funding Summary
- 2,504 Awards in FY97-11
- Recent Applications Recommended for Funding
- Prostate Cancer Consortium Awards
- Program Portfolio
Integration Panels
